In patients with atrial fibrillation and stable coronary artery disease, edoxaban monotherapy led to a lower risk of a composite of death from any cause, myocardial infarction, stroke, systemic embolism, unplanned urgent revascularization, or major bleeding or clinically relevant nonmajor bleeding at 12 months than dual antithrombotic therapy. (Funded by the CardioVascular Research Foundation and others; EPIC-CAD ClinicalTrials.gov number, NCT03718559.).

Introduction: There are limited data regarding the relationship between diabetes control and the risk of subclinical coronary atherosclerosis assessed by coronary computed tomographic angiography (...

NCT 01788592.

Background: Little is known regarding the role of coronary computed tomographic angiography (CCTA) in asymptomatic type 2 diabetic mellitus. To address these issues, we evaluated the clinical usefu...

MASLD is independently associated with incident heart failure beyond traditional CMRFs. Therefore, MASLD's role may warrant consideration in future heart failure risk stratification.

gov; unique identifiers: NCT03718559.

Among patients undergoing low-to-intermediate risk noncardiac surgery >1 year after stent implantation primarily with a DES, in the setting of lower-than-expected event rates, we failed to identify a significant difference between perioperative aspirin monotherapy and no antiplatelet therapy with respect to ischemic outcomes or major bleeding. (Perioperative Antiplatelet Therapy in Patients With Drug-eluting Stent Undergoing Noncardiac Surgery [ASSURE-DES]; NCT02797548).

CCB therapy did not increase adverse cardiovascular events for patients after AMI with preserved LVEF. CCBs can be considered as an alternative for BBs in East Asian patients after AMI with preserved LVEF.

In patients with atrial fibrillation and stable coronary artery disease, edoxaban monotherapy led to a lower risk of a composite of death from any cause, myocardial infarction, stroke, systemic embolism, unplanned urgent revascularization, or major bleeding or clinically relevant nonmajor bleeding at 12 months than dual antithrombotic therapy. (Funded by the CardioVascular Research Foundation and others; EPIC-CAD ClinicalTrials.gov number, NCT03718559.).

Introduction: There are limited data regarding the relationship between diabetes control and the risk of subclinical coronary atherosclerosis assessed by coronary computed tomographic angiography (...

NCT 01788592.